Jiangsu Aidea Pharmaceutical Co Ltd Market Cap ($724.72 Million)
Market Cap & Net Worth: Jiangsu Aidea Pharmaceutical Co Ltd (688488)
Jiangsu Aidea Pharmaceutical Co Ltd market cap. Jiangsu Aidea Pharmaceutical Co Ltd (SHG:688488) has a market capitalization of $724.72 Million (CN¥4.95 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #10031 globally and #2624 in its home market, demonstrating a -3.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Aidea Pharmaceutical Co Ltd's stock price CN¥11.77 by its total outstanding shares 420782808 (420.78 Million). Also see 688488 cash flow metrics for how efficiently the company converts equity into cash flow.
Jiangsu Aidea Pharmaceutical Co Ltd Market Cap History (2020–2026)
Jiangsu Aidea Pharmaceutical Co Ltd market cap history from 2020 to 2026. Data shows change from $1.52 Billion to $724.72 Million (-14.18% CAGR). Check today's stock price for Jiangsu Aidea Pharmaceutical Co Ltd for real-time trading data and today's change.
Jiangsu Aidea Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Jiangsu Aidea Pharmaceutical Co Ltd (688488) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.40x
Jiangsu Aidea Pharmaceutical Co Ltd's market cap is 1.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.52 Billion | $289.06 Million | $39.77 Million | 5.27x | 38.31x |
| 2021 | $958.70 Million | $255.71 Million | -$29.99 Million | 3.75x | N/A |
| 2022 | $648.99 Million | $244.22 Million | -$124.09 Million | 2.66x | N/A |
| 2023 | $770.29 Million | $411.36 Million | -$76.07 Million | 1.87x | N/A |
| 2024 | $483.97 Million | $417.80 Million | -$141.20 Million | 1.16x | N/A |
| 2025 | $1.01 Billion | $720.67 Million | -$19.73 Million | 1.40x | N/A |
Competitor Companies of 688488 by Market Capitalization
Companies near Jiangsu Aidea Pharmaceutical Co Ltd in the global market cap rankings as of November 9, 2026. Also see Jiangsu Aidea Pharmaceutical Co Ltd assets under control for a full breakdown of the balance sheet.
Key companies related to Jiangsu Aidea Pharmaceutical Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Jiangsu Aidea Pharmaceutical Co Ltd (2020–2026)
Market capitalization of Jiangsu Aidea Pharmaceutical Co Ltd from 2020 to today. Between 2020 and today, Jiangsu Aidea Pharmaceutical Co Ltd's market cap moved from $1.52 Billion to $ 724.72 Million, with a yearly change of -14.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥724.72 Million | -27.92% |
| 2025 | CN¥1.01 Billion | +107.76% |
| 2024 | CN¥483.97 Million | -37.17% |
| 2023 | CN¥770.29 Million | +18.69% |
| 2022 | CN¥648.99 Million | -32.31% |
| 2021 | CN¥958.70 Million | -37.07% |
| 2020 | CN¥1.52 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Jiangsu Aidea Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $724.72 Million USD |
| MoneyControl | $724.72 Million USD |
| MarketWatch | $724.72 Million USD |
| marketcap.company | $724.72 Million USD |
| Reuters | $724.72 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules… Read more